Malaysian Healthcare

Business

Gymshark Founder Ben Francis on Billionaire Status: 'It's Just a Number on Paper'

From delivering pizzas to building a global sportswear empire, Ben Francis's journey to a $1.4 billion net worth is a modern business fable. Yet, in a candid podcast interview, the Gymshark CEO argues that equating self-worth with wealth is a 'wildly unproductive way to live,' offering a rare glimpse into the mindset behind the paper fortune.

Feb 2, 2026

Business

Analysts See Long-Term Promise in Legend Biotech's Carvykti Despite Fourth-Quarter Sales Shortfall

While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.

Feb 2, 2026

Business

Intellia Therapeutics Sees Analyst Price Target Surge After FDA Lifts Clinical Hold on Key Gene Therapy Trial

Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.

Feb 2, 2026

Business

Taysha Gene Therapies Gains Momentum as Wells Fargo Raises Target on Rett Syndrome Program

Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.

Feb 2, 2026

Business

Apis Flagship Fund Outperforms in Q4 2025, Cites Stock Picks and Strategy

The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).

Feb 2, 2026

Business

Celcuity's Precision Oncology Push Catches Eye of Top-Performing Fund Apis Capital

Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.

Feb 2, 2026

Business

Stifel Boosts Nurix Therapeutics Price Target to $35, Citing 2026 as Pivotal Year for Key Drug Candidate

Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.

Feb 2, 2026

Business

Jefferies Downgrades Amicus to 'Buy' Amid BioMarin Acquisition, Sees Limited Upside

Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.

Feb 2, 2026

Business

Wisconsin Labor Market Shows Resilience Despite January Layoffs Affecting 366 Workers

Seven Wisconsin employers filed WARN notices in January, yet the state's unemployment rate held steady at a low 3.1%. Economists point to a cooling but stable labor market, with significant workforce changes driven by retirements and sectoral shifts.

Feb 2, 2026

Kansas Overhauls Education Savings Program: Lower Fees, More Choices Arrive in March

TOPEKA — Kansas's popular Learning Quest 529 savings plans are set for a significant upgrade next month, promising families new investment options, enhanced planning tools, and reduced management fees under a new administrator, State Treasurer Steven Johnson announced.

Feb 2, 2026

Business

Palantir's AI Software Growth Exceeds 25% Annually, Phillip Securities Sees Major Upside with $208 Target

Phillip Securities initiates coverage of Palantir Technologies with a Buy rating, citing its AI software segment's robust growth and significant market expansion potential. A new partnership with Innodata aims to enhance Palantir's rodeo analysis platforms through advanced data services.

Feb 2, 2026

Business

IBM Bolsters Enterprise AI Strategy with New Platform, Key Partnership, and PepsiCo CEO Joining Board

IBM intensifies its focus on the enterprise AI market with the launch of its governed deployment platform, a strategic collaboration with e& for regulated sectors, and the appointment of PepsiCo's Ramon Laguarta to its board of directors.

Feb 2, 2026

Business

Edwards Lifesciences: Strong Fundamentals Mask Growth Concerns as Stock Slips

Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.

Feb 2, 2026

World

Former Peruvian Foreign Minister Dies in Brazilian Prison Hospital While Awaiting Extradition

Augusto Blacker Miller, a controversial figure from Peru's Fujimori era, has died in a Rio de Janeiro prison hospital. The 80-year-old, arrested in Brazil last December on an Interpol warrant, succumbed to cardiorespiratory arrest, reigniting debates about justice, aging detainees, and cross-border legal accountability.

Feb 2, 2026

Business

Social Security's 2026 COLA: A Raise That Doesn't Keep Up

Millions of seniors received a 2.8% Cost-of-Living Adjustment this January, but soaring Medicare premiums and a flawed inflation formula mean their real purchasing power continues to erode, highlighting a systemic crisis for retirees.

Feb 2, 2026

As AI Penetrates Patient Care, a Patchwork of State Rules Replaces Federal Guardrails

With pharmaceutical companies increasingly deploying AI in direct-to-consumer platforms, the regulatory landscape remains fragmented. In the absence of comprehensive federal action, states are stepping in with disparate laws to address privacy and safety concerns, creating a complex compliance challenge for the industry.

Feb 2, 2026

US

Congress Returns to Washington in Race Against Clock to Avert Government Shutdown

Lawmakers reconvene Monday as House GOP leadership pushes for rapid passage of a stopgap funding bill to prevent a prolonged partial government shutdown, with tensions high over border security provisions.

Feb 2, 2026

The Silent Inheritance: How Boomers' Reluctance to Discuss Wealth Transfer Risks Family Strife and Financial Chaos

A pervasive culture of silence around estate planning is setting the stage for confusion and conflict as trillions in assets prepare to change hands. Experts warn that avoiding 'the talk' is a disservice to both generations.

Feb 2, 2026

Business

Sanofi's Pipeline Gains Momentum with Key Phase 3 Successes in Rare Disease and Immunology

Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.

Feb 2, 2026

Business

Income Shift: Three Vanguard Dividend ETFs Gaining Favor as Retirement Portfolios Rotate

As market leadership broadens beyond tech, income-focused investors are turning to high-yield dividend ETFs. Vanguard's suite offers diversified, cost-effective options for building retirement income streams in a changing landscape.

Feb 2, 2026